Invitae
United States
272 articles about Invitae
-
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
2/17/2021
Invitae Corporation, a leading medical genetics company, announced financial and operating results for the fourth quarter and full year ended December 31, 2020.
-
Invitae to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2/10/2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at noon Eastern/ 9:00 a.m. Pacific.
-
Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
2/3/2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 financial results on Wednesday, February 17, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific
-
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
1/29/2021
Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a partnership with Invitae, a leading medical genetics company, to launch Amplify TM , a no-charge genetic testing program
-
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering - Jan 26, 2021
1/26/2021
Invitae Corporation announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $51.50 per share.
-
Invitae Announces Pricing of Public Offering of Common Stock - Jan 22, 2021
1/22/2021
Invitae Corporation announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share.
-
Invitae Announces Proposed Public Offering of Common Stock - Jan 20, 2021
1/20/2021
Invitae Corporation announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.
-
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
1/14/2021
-- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster --
-
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
1/11/2021
-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific --
-
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/29/2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George , co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/ 7:50 a.m. Pacific. Following the company presenta
-
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
11/5/2020
Landmark data supporting universal genetic testing in cancer and the utility of germline and somatic testing to improve patient management published
-
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
10/22/2020
Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In
-
Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications
10/6/2020
Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis
-
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
10/5/2020
-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --
-
Invitae Appoints Kimber Lockhart to its Board of Directors
9/11/2020
-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --
-
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer
9/3/2020
-- 1 in 9 men will be diagnosed with prostate cancer in their lifetime -- -- Prostate cancer awareness month calls attention to need for research and testing -- [03-September-2020] SAN FRANCISCO , Sept. 3, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide stu
-
Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference
9/1/2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday, September 14, 2020 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.
-
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
8/4/2020
Introduced expanded services and support for transition to telehealth across customer types
-
Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020
7/21/2020
Invitae Corporation, a leading medical genetics company, announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.
-
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
6/22/2020
Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring